Polycythemia vera: Gender-related phenotypic differences

Internal and Emergency Medicine

Volumn 7, Issue 6, 2012, Pages 509-515

  Landolfi, Raffaele ^a   Di Gennaro, Leonardo ^a   Nicolazzi, Maria Anna ^a   Giarretta, Igor ^a   Marfisi, RosaMaria ^b   Marchioli, Roberto ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Laboratory of Clinical Epidemiology of Cardiovascular Disease   (Italy)

Author keywords

Gender; Myeloproliferative neoplasms; Polycythemia vera; Thrombosis

Indexed keywords

EID: 84869175457     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0634-3     Document Type: Article

References (30)

1. Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L (2010) Polycythemia vera. Intern Emerg Med 5: 375-384.
2. Vannucchi AM (2010) Insights into the pathogenesis and management of thrombosis in polycythemiavera and essential thrombocythemia. Intern Emerg Med 5: 177-184.
3. Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22: 2020-2028.
4. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low dose aspirin in polycythemiavera. N Engl J Med 350: 114-124.
5. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi RM, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109: 2446-2452.
6. Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A (2009) Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J 157: 141-148.
7. Adams KF Jr, Sueta CA, Gheorghiade M, O'Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM (1999) Gender differences in survival in advanced heart failure Insights from the FIRST study. Circulation 99: 1816-1821.
8. Capodanno D, Angiolillo DJ (2010) Impact of race and gender on antithrombotic therapy. Thromb Haemost 104: 471-484.
9. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R, German CML-Study Group (2005) Genderaspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19: 984-989.
10. Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong SM (2010) Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis. Thromb Haemost 103: 710-717.
11. Davis MD, O'Fallon WM, Rogers RS, Rooke TW (2000) Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 136: 330-336.
12. Brière JB (2006) Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 32: 208-218.
13. Stein B, Williams D, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak J, Moliterno A (2010) Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders. Haematologica 95: 1090-1097.
14. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23: 2224-2232.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106: 3143-3421.
16. Lichtman MA, Rowe JM (2004) The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 31: 185-197.
17. Chait Y, Condat B, Casalz-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Brière JB (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic thrombosis. Br J Hematol 129: 553-560.
18. Tondeur S, Boutruche S, Biron-Andréani C, Schved JF (2009) Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 101: 787-789.
19. Bittencourt PL, Couto CA, Ribeiro DD (2009) Portal vein thrombosis and Budd-Chiari syndrome. Clin Liver Dis 13: 127-144.
20. Gangat N, Wolanskhyj AP, Tefferi A (2006) Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates and prognostic implications. Eur J Hematol 77: 327-333.
21. De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5: 487-494.
22. Spanoudakis E, Bazdiara I, Kotsianidis I, Margaritis D, Goutzouvelidis A, Christoforidou A, Tsatalas C, Bourikas G (2009) Hydroxyurea is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia and polycythemiavera patients. Ann Hematol 88: 629-632.
23. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al (2007) Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110: 840-846.
24. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N, Pardanani A, Hanson CA, Ketterling RP (2007) Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21: 2074-2075.
25. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemiavera according to JAK2 V617F mutation status. Haematologica 92: 135-136.
26. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemiavera. Exp Hematol 37: 1016-1021.
27. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108: 3223-3224.
28. Martinelli I, De Stefano V (2010) Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost 103: 1136-1144.
29. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV (1981) Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. Am J Med 71: 595-602.
30. Spanos GA, Bajaj K, Rosner F (1981) Hypocholesterolemia in myeloproliferative disorders. Arch Intern Med 141: 137-138.